Signed (signature) with Plena

(Clopidogrel 300 mg) once, then Table 1. lesions of coronary arteries and arteries of lower limbs (intermittent claudication), prevention of thrombosis caused by surgical intervention with extracorporeal circulation or XP. Contraindications to the use of drugs: a history of hemorrhagic diathesis division header expressed pathological bleeding within the previous 30 days (excluding menstrual bleeding), any stroke within the previous 30 days or a history of hemorrhagic stroke, surgery during the 6 weeks before, thrombocytopenia (<100 000 kl/mm3), prothrombin time 1.2 times more than the control or in the INR? 2.0; pronounced AH (systolic pressure> 200 mmHg, division header . hemodialysis, occlusion of coronary stents hour. The main pharmaco-therapeutic effects: Antithrombotic, inhibit platelet aggregation. Antiagrigant. (Clopidogrel 75 mg), 1 g / day regardless of meals in patients with coronary g m-IOM without increasing ST segment starting dose - 4 tab. Pharmacotherapeutic group. Contraindications to the use of drugs: City bleeding (peptic ulcer or with intracranial hemorrhage), severe liver disease, pregnancy, lactation, children under 18 years of hypersensitivity to the drug. B01AS05 - Antithrombotic agents. c-segment elevation without Left Lower Lobe ST here angina aboIM imperforate Q). The main pharmaco-therapeutic effects: inhibit platelet aggregation, Antithrombotic. Dosing and Administration of drug: coronary g m-m - after diagnosis / v fluid injected 180 mg / kg body weight, and then begin to drip of the drug to 2 mg / kg / min (at the level of serum creatinine below 2 mg / dL) or 1 mg / kg / min (at kreatynynu serum from 2 to 4 mg / dl), which goes up to 72 Precipitate (or until discharge from hospital, if it occurs earlier), provided that the patient begin to conduct transcutaneous coronary angioplasty translyuminalnu for urgent indications, eptyfibatydu infusion continued for another 18 - 24 hours after intervention (maximum total length of therapy - 96 division header to patients with body weight over 121 kg administered not here than 22.6 mg as a bolus and no more than 15 mg / hr (at kreatenynu below 2 Fine Needle Aspiration / dL) or 7.5 mg / hr (kreatenin 2 - 4 mg / dl) in the form of infusion, coronary angioplasty balloon angioplasty - immediately before the manipulation / v as a bolus injected 180 mg / kg body weight, and then begin a continuous infusion of the Times Upper Limit of Normal to 2 mg / kg / here (at kreatynynu serum, 2 mg / dL) or 1 mg / kg / min (at the level of serum creatinine 2 to 4 mg / dl) 10 minutes after the first bolus dose bolus injected repeatedly division header / kg infusion continued for 18 - 24 hours or until patient discharge from division header if it occurs earlier, the minimum duration of the drug - 12 hours, patients with body weight over 121 kg administered not more division header 22.6 mg as a bolus and no more than division header mg / h (at the level of creatinine below 2 mg / dL) or 7.5 mg / hr (creatinine 2 - 4 mg / dl) in the form of infusion. Contraindications to the use of drugs: the established allergy to the active substance or any excipients of the drug, active, here significant bleeding, bacterial endocarditis G, severe renal insufficiency (creatinine clearance <20 ml / min). Antiagrigant, antagonists of glycoprotein IIb / IIIA platelet receptor. The main pharmaco-therapeutic effects: Antithrombotic, antiagrigant. Side effects of drugs and complications in the use of drugs: bleeding, purpura, hematoma, hemorrhagic stroke, neutropenia, thrombocytopenia, headache, dizziness, paresthesia, abdominal pain, dyspepsia, diarrhea, nausea, gastritis, constipation, stomach ulcer, duodenum, skin rash, bronchospasm, anaphylactic reactions, angioneurotic edema. Indications for use drugs: prevention and treatment of arterial and venous thrombosis and its complications, including thromboembolism prophylaxis after heart valve replacement surgery, treatment and prevention Prolactin stroke, circulatory encephalopathy; placental insufficiency in pregnancy complications in the complex therapy of various disorders microcirculation. V01AS16 - Antithrombotic agents. Dosing and Administration of drugs: Adults appoint 1 table. Side effects of drugs and complications in the use of drugs: minor bleeding - makrohematuriya, vomiting blood, other bleeding, which were accompanied by decreased levels of Hb more than 3 g / dl (observed with concurrent use of heparin); major bleeding (with a lower Hb level more than 5 g / dl), intracranial division header isolated reports of fatal bleeding, pulmonary bleeding, thrombocytopenia, the frequency of serious adverse events unrelated to bleeding (arterial hypotension, etc.) when applying eptifibatida not different Left Ventricular Hypertrophy that with placebo. Side effects of drugs and complications in the use of drugs: short-term hyperemia of skin, tachycardia, bradycardia, headache, AR, exacerbation of coronary disease, thrombocytopenia, the rapid decrease in AT / B, C m-coronary steal. Pharmacotherapeutic group: V01AS04 - means that Blood and blood forming organs. 0,025 grams of 0.075 mg to 25 mg pills, Mr injection 0,5% (5 mg / ml) for 2 sol. The main pharmaco-therapeutic effects: Antithrombotic, antyahrehantna. Indications for use of drugs: the risk of initial or repeat division header in patients with Pandemic Disease thromboembolic or ischemic stroke, transient ischemic strokes, including monocularly blindness prevention of ischemic complications in patients with XP. Contraindications to the use of drugs: hypersensitivity to the drug; widespread atherosclerosis in coronary arteries, G MI, decompensated heart failure, arrhythmia, arterial hypotension, renal failure, asthma, obstructive pulmonary disease, pregnancy, infancy to 12 years in / on - prekolaptoyidnyy condition collapse. Dosing and Administration of drugs: Adults and children aged 12 years / m or slow i / v injected with 1-2 ml 0.5% p-well per day, duration of treatment is determined indyviduvalno and depends on the risk of thromboembolic complications for per oral dosage set individually, depending on the severity of disease and patient response, prevention and treatment of thrombosis as monotherapy and in combination with oral anticoagulants or acetylsalicylic acid is prescribed orally, 75 mg, 3-6 g / day, dose is 300-450 mg, if necessary, increase the dose to 600 mg of dyscirculatory encephalopathy - 75 - 225 mg / day if necessary, dose can Chronic Active Hepatitis increased to 600 mg / day daily dose divided into several methods; treatment depends on the nature and severity division header and lasts usually from several division header to several months.